Darzalex
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Darzalex (daratumumab; Johnson & Johnson) targets the transmembrane glycoprotein CD38, which is highly expressed on malignant multiple myeloma cells, but expressed at low levels in other tissues. By binding to this protein, Darzalex induces myeloma cell death by several different mechanisms including apoptosis and antibody- and complement-dependent cytotoxicity.
CONTENTS
4 OVERVIEW
4 Drug Overview
5 Product Profiles
5 Darzalex : Multiple myeloma
31 Darzalex : NHL: Mantle cell lymphoma (MCL)
LIST OF FIGURES
20 Figure 1: Darzalex for multiple myeloma – SWOT analysis
21 Figure 2: Datamonitor Healthcare’s drug assessment summary of Darzalex for multiple myeloma
22 Figure 3: Datamonitor Healthcare’s drug assessment summary of Darzalex for multiple myeloma
25 Figure 4: Darzalex sales for multiple myeloma across the US, Japan, and five major EU markets, by country, 2017–26
34 Figure 5: Darzalex for mantle cell lymphoma – SWOT analysis
LIST OF TABLES
5 Table 1: Darzalex drug profile
7 Table 2: Darzalex pivotal trial data in multiple myeloma
10 Table 3: Darzalex early-phase trial data in multiple myeloma
15 Table 4: Darzalex Phase III trials in multiple myeloma
26 Table 5: Darzalex sales for multiple myeloma across the US, Japan, and five major EU markets, by country ($m), 2017–26
28 Table 6: Patients treated with Darzalex across the US, Japan, and five major EU markets, by country, 2017–26
32 Table 7: Darzalex drug profile
33 Table 8: Darzalex Phase II trial in mantle cell lymphoma
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Pomalyst 
Sign up to the